CD109's involvement in cancers such as lung adenocarcinoma, glioblastomas, hepatocellular carcinomas, breast cancer, leukemia, and squamous cell carcinomas highlights its significant impact on immune responses and oncogenic process. This evidence concerns the gene CD109 and leukemia.